通心络胶囊联合低分子肝素治疗急性冠脉综合征

目的:研究通心络胶囊联合低分子肝素治疗急性冠脉综合征的临床疗效及安全性,为治疗提供依据.方法:122例急性冠脉综合征患者随机分为治疗组和对照组各61例.在常见治疗基础上,对照组给与低分子肝素,治疗组在对照组治疗基础上,加用通心络胶囊,疗程均为4周,治疗结束后比较两组患者的心脏功能、心电图疗效、心绞痛疗效、临床总有效率以及不良心血管事件的发生率.结果:治疗组患者的心脏左心室射血分数(LVEF)、心输出量(C0)以及E峰A峰比值均有明显提高,优于对照组(P＜0.05)；治疗组患者心电图总有效率63.9％,与对照组57.4％相当,组间无统计学差异；治疗组患者心绞痛发作次数及持续时间明显少于对照组(P＜0.05)；治疗组临床总有效率95.1％,对照组73.8％,治疗组高于对照组(P＜0.05)；治疗组患者不良心血管事件的发生率6.6％,明显低于对照组29.5％ (P＜0.05).结论:通心络胶囊联合低分子肝素治疗急性冠脉综合征临床效果显著,改善心脏功能及心绞痛症状作用更明显,临床有效率更高,不良心血管事件更少,值得临床推广应用.

Efficacy and Safety of Tongxinluo Capsule Combined with Low-molecular-weight Heparin in Treatment of Acute Coronary Syndrome

Objective: To investigate the efficacy and safety of Tongxinluo capsule combined with low-molecular-weight heparin in the treatment of acute coronary syndrome, to provide evidence for clinical application of the remedy. Method: One hundred and twenty-two patients suffered from acute coronary syndrome were divided into two groups randomly, the control and the treatment group. The control group was given the low-molecular-weight heparin with the basic therapy, and the treatment group was given the Tongxinluo capsule on the basis of the control intervention. The treatment duration was both 4 weeks, the cardiac function, electrocardiogram curative effect, total effect and adverse effect were compared. Result: The left ventricular ejection fraction(LVEF), cardiac output(co) and the ratio of E peak(E/A) over A peak in treatment group were significantly improved compared with those in the controls(P<0.05). The total effect in electrocardiogram curative was 63.9% in treatment group and 57.4% in the control group, the difference was not statistically significant. Anginal attacks and duration in treatment group were obviously less than those in the controls. Total clinical effect was 95.1% in the treatment group and 73.8% in the controls (P<0.05). The incidence of cardiovascular events is 6.6% in treatment group and 39.5% in control, The adverse effect was significant lower in treatment group (P<0.05). Conclusion: Tongxinluo capsule combined with western medicine is effect for the treatment of acute coronary syndrome. The treatment shows obviously improved cardiac function and angina symptoms, with higher clinical efficient and less adverse cardiovascular events. So, it is worth clinical application.